We develop antibodies and immunoassays

capable of detecting amino acids, saccharides, neurotransmitters and neuromediators, lipids, toxins… and drugs!

Through our range of ELISA kits and immunoglobulins, Immusmol open the way of low molecular weight entities for new set of possibilities in research, diagnostic and therapy.

L-Arginine is a key amino acid in the immune regulation and can be targeted as part of an anti-tumor response. We have thus developed and validated an ELISA kit for the detection and quatification of L-Arginine in biological samples.

Among mechanisms associated with cancer immune evasion, the activation of the Kynurenine Pathway (KP) is known to play a key role and has thus been proposed as a therapeutic target to improve current immune checkpoint blockade-based immunotherapies.

2023 is near, but there’s still time to check out our best highlights of the second half of 2022! Stay connected, great things are coming next year!

L-Arginine is a key amino acid in the immune regulation and can be targeted as part of an anti-tumor response. We have thus developed and validated an ELISA kit for the detection and quatification of L-Arginine in biological samples.

Don’t miss this offer! Take a tour of our product webpage to select your favorites and benefit from this season’s offer to try them!

Glutamate (Glu) and gamma-aminobutyric acid (GABA) are the major neurotransmitters (NTs) in the brain and work together through balanced interactions to control many processes. Imbalanced interactions can cause diseases, that impair intracellular contents of Glu and GABA as well as their anatomical and functional network.

We developed and validated a new L-Histidine ELISA kit (#IS-I-1300R) which allows for L-His quantitation in plasma samples. The assay requires a low sample volume of 10μL and is characterized by a 1.4µM sensitivity.

New highlight in Annals of Oncology!
In this study, Peyraud at al. show that plasmatic level of L-Arginine (Arg) is associated with clinical outcome of patients treated with immune checkpoint blockers (ICB). Using an ELISA approach for Arg quantification (#IS-I-0400R) applied on two independent cohorts, authors demonstrated that low plasmatic level of Arg was associated with a worse clinical outcome.